Research programme: phosphodiesterase IV inhibitors - BTG
Alternative Names: PDE4 inhibitors research programme - BTG; Phosphodiesterase IV inhibitors research programme - BTG; Research programme: PDE4 inhibitors - BTGLatest Information Update: 21 Aug 2019
At a glance
- Originator BTG
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allergic contact dermatitis; Hypersensitivity; Inflammation; Multiple sclerosis; Osteoporosis; Rheumatoid arthritis; Septic shock
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 20 Jul 2011 Discontinued - Preclinical for Allergic contact dermatitis in USA (PO)
- 20 Jul 2011 Discontinued - Preclinical for Hypersensitivity in USA (PO)